Moderna Inc. (NASDAQ: MRNA) shares surged approximately 6.21% on Tuesday, June 23, 2026, driven by a unanimous FDA advisory committee vote favoring its mRNA-1010/mFLUSIVA seasonal flu vaccine for adults aged 50 and older. The stock climbed from roughly $47 to $63 over the preceding month,...
Moderna (MRNA) stock has surged for a fifth consecutive day following the publication of FDA briefing documents indicating that immunogenicity data from its mFlusiva flu shot may support effectiveness in adults aged 65 and older. This represents a significant regulatory shift, as the FDA had...
Moderna (MRNA) shares surged 17.4% in the afternoon session after the company settled a long-running patent dispute with Arbutus Biopharma and Genevant Sciences. The agreement, valued at up to $2.25 billion, resolves legal uncertainties surrounding the technology used in its COVID-19 vaccine and eliminates future...
Moderna Inc (MRNA) reported Q1 2026 revenue of $400 million, representing a significant $300 million year-over-year increase, with costs of sales rising to $955 million primarily due to an $878 million litigation settlement related to Arbutus and Genevant. On a GAAP basis, the company recorded...
Moderna (MRNA) shares surged 14% to $68 in Friday afternoon trading, reaching a new 52-week high of $69.29. The rally significantly outpaced peers Merck (MRK), which rose 2%, and Pfizer (PFE), which gained 2%. Analysts attribute the move to momentum from a recent FDA advisory...
Moderna (MRNA) shares surged 9% today, extending a remarkable 94% gain year-to-date to trade near $57. This performance significantly outpaces peers Pfizer (PFE), which is up 4%, and Novavax (NVAX), which is up 41%. The rally is driven by corporate restructuring rather than new clinical...
The article argues that while Moderna (MRNA) recently surged 63% year-to-date following a Q1 revenue triple, its long-term fundamentals remain weak. Full-year 2025 revenue collapsed to $1.94 billion, a roughly 40% drop, with management projecting only up to 10% growth for 2026 off this depressed...
Moderna (NASDAQ:MRNA) was ranked number one on TIME's 2026 list of the World's Most Impactful Companies, a distinction based on the Upright Project's Net Impact Model which evaluates net-positive contributions across Society, Knowledge, Health, and Environment. The recognition highlights Moderna's status as a pioneer in...
Moderna (MRNA) shares surged 16% on March 4 after the company reached a settlement with Arbutus Biopharma and Genevant Sciences regarding patents for its COVID vaccines. The agreement includes a one-time payment of $950 million to Moderna, with no future royalties required. This resolution removes...
Brookline Capital Markets analyst L. Cann raised its Q2 2026 earnings per share (EPS) estimate for Moderna to ($1.97), a slight improvement from the previous forecast of ($1.98). The firm also provided forward guidance, projecting Q3 EPS at ($1.30), Q4 at ($2.16), full-year 2026 EPS...
Amundi reduced its holdings in Moderna, Inc. (NASDAQ:MRNA) by 20.9% during the first quarter, selling 238,790 shares to retain a position valued at approximately $45.96 million. While Amundi decreased its stake, other institutional investors like MUFG Securities EMEA and Flagship Harbor Advisors established new positions,...
Moderna (MRNA) shares surged to a 52-week peak of $81.42 on July 6, marking a 169% annual gain and pushing the market cap to approximately $32.2 billion. This rally was driven by renewed enthusiasm for mRNA technology, including FDA advisory panel endorsement for its seasonal...
Simply Wall St analyzes Moderna (MRNA), noting a recent surge with a 51.4% year-to-date return and a current price of $46.71. The article questions whether the market has overvalued the stock, citing a DCF model that projects significant future cash outflows until 2030, resulting in...
Moderna (MRNA) shares rose 4.6% following a post-earnings repricing driven by stronger international vaccine deliveries and reiterated growth frameworks for 2026. The company reported first-quarter 2026 revenue of $389 million, with approximately 80% derived from international markets under long-term partnership agreements. Management highlighted a plan...
BioNTech is generating significant headlines with dual momentum in its oncology pipeline and an escalating legal strategy against competitors. At the AACR Annual Meeting 2026, the company presented updated Phase 1 data for its personalized mRNA cancer vaccine, Autogene Cevumeran (BNT122), developed in collaboration with...
Moderna Inc. (NASDAQ: MRNA) announced on Tuesday that the European Commission has granted marketing authorization for mCOMBRIAX, a combined vaccine targeting both COVID-19 and influenza. The authorized product, identified by its code mRNA-1083, utilizes messenger RNA technology to prevent illness from both viruses. This regulatory...
The article compares ImmunityBio (IBRX) and Moderna (MRNA) as investment options, highlighting their distinct business models. ImmunityBio relies heavily on its single marketed drug, Anktiva, which saw net product revenues surge to $113 million in 2025, driven by repeat prescribing and a BCG shortage. The...
Moderna (NASDAQ:MRNA) saw unusual bullish activity as traders purchased 113,636 call options on Friday, representing a 47% increase over the average volume. Despite this positive options flow, the stock traded down $4.01 to reach $49.56 during mid-day trading, with volume at 7.08 million shares compared...
Moderna (MRNA) shares fell 7.8% in a post-rally pullback as investors weighed recent legal-cost clarity against fresh regulatory uncertainty regarding its standalone flu vaccine. The selloff appears driven by profit-taking and sentiment shifts rather than a single new headline, with traders reassessing the timeline for...
A study published in the journal Vaccines suggests that Moderna's COVID-19 vaccine (mRNA-1273) presented greater risks than benefits for males aged 18-25, contradicting the FDA's 2022 risk-benefit analysis. The research found that among this demographic, the vaccine was associated with 8% to 52% more hospitalizations...
